Top Breast Cancer Liquid Biopsy Companies

Breast Cancer Liquid Biopsy Market size was valued at USD 511.7 Million in 2024 and is poised to grow from USD 627.85 Million in 2025 to USD 3225.62 Million by 2033, growing at a CAGR of 22.7% during the forecast period (2026–2033).

Key vendors include F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Illumina Inc., Guardant Health Inc., QIAGEN, Biocept Inc., Thermo Fisher Scientific, Adaptive Biotechnologies, Myriad Genetics, Fluxion Biosciences Inc., Biodesix, Exosome Diagnostics Inc., Epic Sciences, PapGene, Pathway Genomics (OME Care), Agena Bioscience, MDxHealth, Janssen Diagnostics, and Abbott.

The key driver is the increasing adoption of liquid biopsy techniques as a non-invasive alternative to traditional tissue biopsies. Liquid biopsies enable analysis of circulating tumor cells and cell-free DNA, supporting treatment decisions, detection of resistance mutations, and personalized treatment strategies.

A key trend is the growing integration of liquid biopsy with personalized and precision oncology. Advances in circulating tumor DNA (ctDNA) analysis and molecular profiling are improving treatment selection, monitoring treatment response, and detecting resistance mutations in breast cancer patients.

North America accounted for the largest share of the Breast Cancer Liquid Biopsy Market, supported by the strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe also demonstrates significant growth due to increasing awareness and R&D activities.